MentionFox
Home › funding signals › Cue Biopharma, Inc.
Form D · on the record

Cue Biopharma — $30M Form D filing, May 2026

Cue Biopharma, Inc. filed a Form D with the Securities and Exchange Commission on 2026-05-14.

Cue Biopharma, Inc. filed a Form D notice of an exempt securities offering with the SEC on May 14, 2026. Cue Biopharma, Inc. trades on Nasdaq as CUE; it was formerly Imagen Biopharma, Inc. The filing reports $30M sold. Its industry group is Biotechnology. It names Shao-Lee Lin (Executive Officer, Director), Colin Sandercock (Executive Officer), Daniel Baker (Executive Officer) (SEC Form D, May 14, 2026).

In its own words: “CUE Biopharma is a clinical-stage biopharmaceutical company focused on advancing a robust portfolio of therapies.” (cuebiopharma.com, checked October 31, 2026)

Sell to companies like Cue Biopharma, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

88 companies raised this week, 1 had other signals.

Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.

fal - Features & Labels, Inc.$1BAI and software
fal - Features & Labels, Inc.$350MAI and software
SIERRA INTERNATIONAL NETWORK INC$300MAI and software
Zai Lab Ltd$250MBiotech
Databento Inc.$100MAI and software
Check one company free All companies that raised this week

5 more Biotechnology raises in Massachusetts, May 2026 ↓

Is this your company?

Key facts

Run the free check on Cue Biopharma, Inc. →

Cue Biopharma, Inc.

New Form D on file · 2026-05-14 · the record

$30M
raise on the record
D
filing
118
investors in
MASSACHUSETTS
based
Open the record →

What the record says

FilingForm D
Filed2026-05-14
Industry groupBiotechnology
Entity typeCorporation
Incorporated inDELAWARE
BasedBOSTON, MASSACHUSETTS
CIK1645460
Accession0001645460-26-000003

Pitching, partnering or investing alongside them? See who really runs and owns Cue Biopharma, Inc.

Free to see. No signup.

Keep reading

More on the people and the money behind Cue Biopharma, Inc., from the filings we hold.

Raised through the same sales agent

Newbridge Securities Corporation received sales compensation on this raise and on 2 other raises we hold, nearest in date first:

More raises like this

Biotechnology raises by companies based in Massachusetts, filed in May 2026, largest first.

What do you want to do with Cue Biopharma, Inc.?

Get the full cited report on Cue Biopharma, Inc.

What the filing shows about Cue Biopharma, Inc.

  • 118 investors had already put money in when it filed.
  • The filing names 9 people as officers, directors or promoters.

Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Cue Biopharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

See a sample report

Just raised? Your investors will ask for updates.

The weeks after a raise are when investors, other founders and press look Cue Biopharma, Inc. up. FoxPlug is your startup's chief of staff: it reads your whole stack and tells you what to fix, what to say and what to skip, for founders shipping with Claude Code, Codex or Cursor. It drafts your monthly investor update from your real numbers, and its free tools need no account. GetFoxChat puts an AI operator on Cue Biopharma, Inc.'s own site, named as you like, so the visitors this record sends you don't read one page and leave.

Who the filing names, and in what role

The filing gives Cue Biopharma, Inc.'s address as 40 Guest Street, Boston, MA 02135.

What the filing says

  • Offered: $29,999,992. Sold: $29,999,992. Left to sell: nothing, all of it is sold. (filing)
  • Investors: 118 had already invested. (filing)
  • Date of first sale: May 4, 2026. (filing)
  • Types of securities: Options, warrants or other rights to acquire another security; Securities to be acquired on exercise of an option, warrant or other right; Other: Pre-funded warrants to purchase shares of Common Stock. (filing)
  • Item 16: the filing reports that none of the proceeds goes to executive officers, directors or promoters. (filing)

This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.

Order the Full Report on Cue Biopharma, Inc. See pricing

Is Cue Biopharma, Inc. a real, registered company?

Cue Biopharma, Inc. is a registered filer with the SEC (CIK 1645460) and has filed since 2022-11-21. 3 filings are on record, the latest on 2026-07-22.

A filing shows the company exists and what it reports about itself. It is not an audit or a rating.

Who runs Cue Biopharma, Inc.?

Cue Biopharma, Inc.'s Form D of 2026-05-14 names Shao-Lee Lin, Colin Sandercock, Daniel Baker and 6 more as its officers, directors or promoters.

How much has Cue Biopharma, Inc. raised?

Its new offerings report $110M sold across 3 offerings, as its own filings state.

Filing history · 3 filings on this registrant
Form D · 2022-11-21 · $30MForm D · 2026-05-14 · $30M · this pageForm D · 2026-07-22 · $50M 2022-11-21 2026-07-22

Each marker is one filing. The larger marker is the filing this page is about.

Biotechnology · by week
This raise, $30M, filed week of May 11

Trailing twelve months. 771 filings in Biotechnology, totalled by week. The dot is this raise, $30M, on the same scale — one filing against the whole group's total, so it sits low by construction.

Want the whole picture on Cue Biopharma, Inc.?

What the filing shows about Cue Biopharma, Inc.

  • 118 investors had already put money in when it filed.
  • The filing names 9 people as officers, directors or promoters.

Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Cue Biopharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Cue Biopharma, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    2 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The full profile

Checking your access…

Sourced from the filing index on sec.gov.

Follow this companyRSS

Tools for this story

Each opens in a new tab, filled in for Cue Biopharma, Inc.. With no account yet, you sign up free and land on the result.

More on Cue Biopharma, Inc.

Share this page

Is this your company?

Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.

Cue Biopharma, Inc.: Raised $30M, Form D filed 2026-05-14
Share on LinkedIn Share on X Download image

Cite this page

Permanent URL: https://mentionfox.com/funding/cue-biopharma-inc-form-d-26000001
Last updated 2026-10-20
Primary record: SEC filing 1 · SEC filing 2
Cue Biopharma raised $30M — SEC Form D filing, May 2026. MentionFox, 2026-10-20. https://mentionfox.com/funding/cue-biopharma-inc-form-d-26000001